Experimental mRNA CAR-T therapy targets autoimmune diseases in first human trial
NCT ID NCT07629596
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests Arnovie101, an mRNA-based CAR-T therapy given directly into the bloodstream, in 5 people with lupus or autoimmune hemolytic anemia. The goal is to see if it is safe and how the body processes it. Researchers will also check if it reduces disease activity over 12 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Arnovie101 (mRNA-based CAR-T therapy)
- What this could lead to
- If successful, this could point toward a new way to treat autoimmune diseases like lupus without needing lifelong medication.
- What could go wrong
- This is a very early, small trial (only 5 people) focused on safety. It may not work, and there are risks like severe immune reactions or organ damage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE HEMOLYTIC ANEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing GoBroad Boren Hospital
RECRUITINGBeijing, Beijing Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new biologic tame lupus flares?
- Could a single injection tame lupus and Sjögren's?
- Can a single infusion tame tough lupus?
- Can engineered immune cells tame autoimmune anemia?
- Could a simple blood test predict clot risk in antiphospholipid syndrome?
- Can a single drug calm three different autoimmune diseases? a new trial puts ATG-201 to the test.